How Long Does Stem Cell Therapy Last for Knees?
Relief from stem cell therapy for knees has been shown to last up to 12 months in randomized trials, and no trial has tested whether it lasts longer. Onset is gradual rather than immediate, and the measured benefit is modest. Our recovery and longevity library covers what the research establishes.
3 min read
How Long Does Relief Last After Stem Cell Therapy for Knees?
Trials measure outcomes at 6 and 12 months, and durability past 12 months has not been tested under randomized conditions. Clinics commonly quote 12 to 24 months from their own patient follow-up. That figure is observational, uncontrolled, and collected by the party selling the treatment, so it carries less weight than a trial result.
- Onset of noticeable change: 6 to 12 weeks
- Longest randomized follow-up published: 12 months
- Duration commonly quoted by clinics: 12 to 24 months
- Evidence supporting that longer figure: observational only
Why Does Onset Take Weeks Rather Than Days?
Mesenchymal cells work through signaling rather than direct replacement of cartilage. That signaling influences the local inflammatory environment across weeks, which is why any change is gradual. Nothing in the mechanism produces a same-day result, and a clinic promising one is describing something other than cell biology.
How Does That Compare to Cortisone?
A cortisone injection reduces pain within days by suppressing inflammation directly, though relief typically fades within 3 months. That speed difference is the clearest practical contrast between the two, and it cuts in both directions. Patients expecting same-week change consistently judge a cell-based protocol too early to be fair to it.
What 5 Factors Shorten the Effect?
Five variables reduce how long any relief lasts.
- Cartilage loss at bone-on-bone stage leaves less tissue for signaling to influence.
- Body weight increases joint load with every step taken.
- Repetitive high-impact activity resumed too early raises mechanical stress.
- Untreated joint misalignment concentrates load on a single compartment.
- Smoking reduces local blood supply and slows every repair process.
Three of those 5 are modifiable first. Research on knee osteoarthritis found that each pound of weight lost reduces knee load fourfold per step, so 10 pounds removes roughly 40 pounds of force per stride.
When Is a Repeat Injection Considered?
Repeat treatment is discussed when function declines, not on a fixed schedule. A provider should reassess imaging and range-of-motion scores against the pre-treatment baseline before recommending a second round. A repeat offered by calendar date rather than by measured decline is a sales prompt, not a clinical one.
What Does a Second Round Cost?
Cost weighs heavily in that decision, particularly given the evidence below. A second round carries the same price as the first with no accumulated discount. Our breakdown of how much stem cell therapy for knees costs covers what a repeat involves.
What Does the Evidence Actually Show?
The evidence is weaker than clinic marketing suggests. A 2025 Cochrane review of stem cell injections for knee osteoarthritis found a 1.2-point greater pain reduction on a 10-point scale compared with placebo, on low-certainty evidence.
How to Read a Duration Claim
Duration figures describe reported outcomes, not a regulated performance standard. The FDA has approved no stem cell product for arthritis or joint pain, so a candidacy review for regenerative stem cell therapy should open with that fact.
Frequently Asked Questions
Does stem cell therapy regrow knee cartilage?
No published evidence shows reliable cartilage regrowth in human knees. Reported benefit centers on pain and function scores rather than measurable cartilage volume on imaging. Treat any regrowth claim as a marketing statement rather than a clinical finding.
How does it compare to knee replacement?
Knee replacement has far stronger long-term data. Pooled national registry data covering roughly 300,000 procedures found about 82 percent of total knee replacements still in place at 25 years. The two are sequential options rather than competing ones.
Who is a poor candidate?
Patients with bone-on-bone arthritis, active joint infection, or an untreated ligament tear are typically poor candidates. A recent MRI is standard before evaluation. Our overview of joint pain and sports injury covers what a candidacy review requires.
